Filter Results:
(3)
Show Results For
- All HBS Web
(3)
- Research (2)
- Faculty Publications (2)
Show Results For
- All HBS Web
(3)
- Research (2)
- Faculty Publications (2)
Page 1 of 3
Results
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- January 2014
- Teaching Plan
MedImmune Ventures
By: Richard Hamermesh and Andrew Otazo
"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets. View Details
Keywords: MedImmune Ventures; NeuProtect; Corporate Venture Capital; Ron Laufer; Australia; Starfish Ventures; AstraZeneca; MEVE; Healthcare; Startup; Venture Capital; Business Startups; Health Industry; Australia; United States
Hamermesh, Richard, and Andrew Otazo. "MedImmune Ventures." Harvard Business School Teaching Plan 814-039, January 2014.
- Web
Recruiting Partners - Health Care
Brighton Health Group Bristol-Myers Squibb Broadview Ventures Business Talent Group C C. R. Bard, Inc. C1 Consulting, LLC Caladrius Biosciences California Family Health Council Call9 Cambia Health Solutions CAMRIS International Canon USA,... View Details